–
Статьи в журналах
-
- 2022 A phase-II study of atezolizumab in combination with obinutuzumab or rituximab for relapsed or refractory mantle cell or marginal zone lymphoma or Waldenström’s macroglobulinemia
- Panayiotidis P., Thieblemont C., Ptushkin V., Niebla A., García-Sanz R., Le Gouill S., Stathis A., Тумян Г.С., и др
- в журнале Clinical lymphoma, myeloma & leukemia, издательство Cancer Media Group (United States), том 63, № 5, с. 1058-1069
-
- 2020 Primary Analysis of the Tegar Study: A Phase II Study Exploring the Safety and Efficacy of Atezolizumab in Combination with Obinutuzumab or Rituximab in Patients with Relapsed or Refractory (R/R) Mantle Cell Lymphoma (MCL), Marginal Zone Lymphoma (MZL), o
- Panayiotidis P., Tumyan G., Thieblemont C., Ptushkin V., Niebla A.M., Garcia-Sanz R., Zaritskey A., et al.
- в журнале Blood, издательство American Society of Hematology (United States), № 136